Japer Therapeutics Equity Warrants Exp 24th Sep 2026 JSPRW:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
Last | 4:00 PM EDT
0.1925UNCH (UNCH)
Volume
224
52 week range
0.04 - 0.38
Loading...
  • Open0.1925
  • Day High0.1925
  • Day Low0.1925
  • Prev Close0.1925
  • 52 Week High0.38
  • 52 Week High Date01/18/24
  • 52 Week Low0.04
  • 52 Week Low Date01/02/24

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.02M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open0.1925
  • Day High0.1925
  • Day Low0.1925
  • Prev Close0.1925
  • 52 Week High0.38
  • 52 Week High Date01/18/24
  • 52 Week Low0.04
  • 52 Week Low Date01/02/24
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.02M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Japer Therapeutics Equity Warrants Exp 24th Sep 2026

 

Profile

MORE
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The...
Thomas Wiggans
Chairman of the Board
Ronald Martell
President, Chief Executive Officer, Director
Jeetinder Mahal
Chief Operating Officer
Herb Cross
Chief Financial Officer, Corporate Secretary
Address
2200 Bridge Pkwy Suite #102
Redwood City, CA
94065
United States